Complete 2025 Guide to Obesity Drugs From Orlistat to Triple Agonists
Mayo Clinic review covers every FDA-approved obesity medication plus pipeline drugs, with head-to-head weight loss data and clinical best practices.
Summary
This 2025 narrative review from Mayo Clinic's gastroenterology division comprehensively maps the obesity pharmacotherapy landscape as of February 2025. It covers FDA-approved agents — orlistat, phentermine, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide — alongside pipeline drugs including dual glucagon/GLP-1 agonists, triple GLP-1/GIP/glucagon agonists, oral GLP-1 formulations, and amylin agonists. The review grounds each drug in the underlying gut-brain appetite physiology, compares weight loss efficacy across agents, summarizes cardiovascular and metabolic benefits beyond weight, and provides practical guidance for clinicians on monitoring, dose adjustment, and adjunct lifestyle strategies.
Detailed Summary
Obesity now affects 43% of the US population and has doubled globally between 1990 and 2022, generating an estimated $172 billion in annual US healthcare costs. Despite decades of research, effective pharmacotherapy has historically been limited, but the past decade has seen a dramatic expansion of treatment options. This Mayo Clinic review, authored by Fredrick, Camilleri, and Acosta and published in Clinical Pharmacology: Advances and Applications, synthesizes the full spectrum of anti-obesity medications available or in late-stage development as of early 2025, grounding each agent in the gut-adipose-brain appetite physiology that makes them work.
The review opens with a detailed mechanistic framework covering the three homeostatic phases of food intake — hunger, satiation, and postprandial satiety — driven by hypothalamic neuropeptides (NPY, AgRP, CGRP), vagal signals, and a cascade of gut hormones including ghrelin, GLP-1, GIP, CCK, PYY, and insulin-like peptide 5 (INSL5). This physiologic grounding is essential for understanding why newer incretin-based agents outperform older sympathomimetics. Older non-incretin agents show modest efficacy: orlistat achieves only 2.8–4.8% body weight loss versus placebo at 52 weeks, while phentermine yields 7–8.3% at 12 months but is limited to 12-week use due to cardiovascular risks. Phentermine-topiramate reaches 9.8–10.9% weight loss at 12 months, and naltrexone-bupropion achieves 6.1–9.3%, both with meaningful but limited tolerability profiles.
The GLP-1 receptor agonists represent a step-change in efficacy. Liraglutide (3 mg SC daily) produces 6–8% body weight loss at 12 months, while semaglutide (2.4 mg SC weekly) achieves 10.76–14.9% total body weight loss at 52 weeks in the STEP trials. Tirzepatide, the dual GLP-1/GIP co-agonist, surpasses both: the SURMOUNT trials demonstrated 13.9–17.5% total body weight loss at 52 weeks and up to 18.4% at 72 weeks. Critically, semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease, establishing cardiovascular benefit independent of weight loss alone. Tirzepatide similarly demonstrated reductions in sleep apnea severity and improvements in heart failure with preserved ejection fraction.
The pipeline section is particularly forward-looking. Dual glucagon/GLP-1 agonists (survodutide, mazdutide) leverage glucagon's thermogenic and lipolytic effects alongside GLP-1's satiety signaling. Triple agonists targeting GLP-1, GIP, and glucagon simultaneously — including retatrutide and LY3437943 — show early Phase 2/3 data suggesting weight loss potentially exceeding 20–24% total body weight. Oral semaglutide formulations and novel amylin agonists (cagrilintide, alone or combined with semaglutide as CagriSema) round out the pipeline, with CagriSema Phase 3 data anticipated to show weight loss approaching or exceeding 25%. Setmelanotide is highlighted for rare monogenic obesities involving MC4R pathway defects.
The review concludes with practical clinical guidance: initiating lifestyle interventions concurrently with pharmacotherapy, monitoring weight loss response at 12–16 weeks to assess medication adequacy, titrating doses to maximize tolerability, and considering medication sequencing or combination strategies for patients with insufficient response. The authors note that 5–10% body weight loss is sufficient to meaningfully reduce most obesity-related comorbidities, while bariatric surgery thresholds (>25% loss) are now being approached pharmacologically. Limitations include the narrative rather than systematic design, potential for publication bias in cited trials, and the rapidly evolving nature of the field.
Key Findings
- Tirzepatide (dual GLP-1/GIP agonist) achieved 13.9–17.5% total body weight loss at 52 weeks and up to 18.4% at 72 weeks in SURMOUNT trials — the highest efficacy among currently approved agents
- Semaglutide 2.4 mg SC weekly produced 10.76–14.9% total body weight loss at 52 weeks and reduced MACE by 20% in the SELECT cardiovascular outcomes trial
- Liraglutide 3 mg SC daily yielded 6–8% body weight loss at 12 months, with nausea reported in 39–42% of patients
- Phentermine-topiramate achieved 9.8–10.9% body weight loss at 12 months; orlistat produced only 2.8–4.8% weight loss versus placebo at 52 weeks
- Triple GLP-1/GIP/glucagon agonists (retatrutide, LY3437943) in Phase 2/3 trials show early signals of >20% total body weight loss, potentially approaching bariatric surgery outcomes
- CagriSema (cagrilintide + semaglutide amylin/GLP-1 combination) Phase 3 data anticipated to demonstrate weight loss approaching 25% total body weight
- Orlistat's XENDOS trial showed 37.3% reduction in risk of developing type 2 diabetes (cumulative incidence 6.2% vs 9.0% placebo) over 4 years despite modest weight loss
Methodology
This is a narrative review, not a systematic review or meta-analysis, based on targeted PubMed, MEDLINE, and Google Scholar searches using keywords including obesity, pharmacotherapy, GLP-1, bariatric, and anti-obesity medications, with literature included up to February 1, 2025. Active trials were identified via ClinicalTrials.gov. The review synthesizes pivotal randomized controlled trials for each approved agent alongside Phase 2 and 3 trial data for pipeline compounds. No formal risk-of-bias assessment or PRISMA methodology was applied, which is a limitation inherent to the narrative format.
Study Limitations
As a narrative rather than systematic review, the paper is susceptible to selection bias in which studies were included and how results were weighted. The rapidly evolving pipeline means some Phase 3 data cited as anticipated may have since been published or modified. The authors are affiliated with Mayo Clinic's gastroenterology division; no explicit conflicts of interest are declared in the available text, though the field broadly involves industry-funded trials that underpin the efficacy data reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.